热门资讯> 正文

Aurinia与Teva和解Lupkynis专利诉讼

2026-08-20 05:12

Teva Pharmaceutical Industries (TEVA) will not be able to launch a generic version of Aurinia Pharmaceuticals' (AUPH) Lupkynis (voclosporin) until Dec. 7, 2036, at the earliest under a settlement.
Teva had filed an Abbreviated New Drug Application to sell generic voclosporin.
Aurinia has patent litigation against several other generic companies seeking to market generic voclosporin.

More on Aurinia Pharma, Teva Pharmaceutical

Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Teva's Re-Rating Still Has Room To Run
Teva gets FDA priority review for Tourette syndrome therapy
Teva snaps six-session rally, closes flat in the red

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。